No products were found matching your selection.
What Is CJC-1295?
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue engineered with a Drug Affinity Complex (DAC) that extends its half-life to approximately 8 days, enabling once-weekly subcutaneous administration. It stimulates pulsatile growth hormone secretion from the anterior pituitary without replacing the body’s own GH production. As a research compound, CJC-1295 is primarily evaluated in protocols aimed at optimizing GH, body composition, and recovery. Practitioners researching whether to buy CJC-1295 should distinguish clearly between DAC and non-DAC formulations before evaluating any online or wholesale supplier listing.
What sets CJC-1295 with DAC apart from other GHRH analogues is its prolonged duration of action. The Drug Affinity Complex binds to circulating serum albumin, keeping the peptide active in plasma for days rather than minutes. Published pharmacokinetic studies report an estimated half-life of approximately 5.8 to 8.1 days for CJC-1295 with DAC, compared with roughly 10–20 minutes for Sermorelin and approximately 30 minutes for Modified GRF 1-29, commonly referred to as CJC-1295 without DAC.
This extended half-life has been shown in early human research to support prolonged increases in GH and IGF-1 after subcutaneous administration. In investigational settings, that longer duration has led to once-weekly dosing discussions for DAC-containing formulations, although no FDA-approved dosing standard exists. It is worth noting that CJC-1295 is not recombinant growth hormone — it works upstream, prompting the body to release its own GH through the GHRH receptor.
When evaluating CJC-1295, it is important to distinguish between its two main formulations:
- CJC-1295 with DAC: Long-acting formulation with albumin binding and once-weekly dosing.
- CJC-1295 without DAC (Modified GRF 1-29): Short-acting formulation with a half-life of approximately 30 minutes that typically requires multiple daily administrations.
CJC-1295 is not approved by the U.S. Food and Drug Administration for therapeutic use and is generally classified as a research compound.
A large share of practitioner interest in CJC-1295 centers on its combination with Ipamorelin. Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release via the growth hormone secretagogue receptor (GHS-R), acting through a distinct pathway from CJC-1295’s GHRH receptor activity. Because CJC-1295 and Ipamorelin act through different receptor pathways, they are often discussed together in peptide research; however, controlled clinical evidence supporting combination use remains limited.
Mechanism of Action
CJC-1295 targets GHRH receptors on somatotroph cells (the pituitary’s growth hormone-producing cells) within the anterior pituitary gland. Once those receptors are activated, the pituitary synthesizes and releases endogenous growth hormone in pulses, which then signals the liver to produce IGF-1.
The DAC modification is what makes the compound pharmacologically distinctive. After subcutaneous administration, the DAC component binds to circulating albumin, forming a sustained peptide reservoir in the bloodstream. This protects CJC-1295 from the rapid clearance and enzymatic breakdown that normally limit native GHRH and shorter-acting analogues to a window of minutes.
As GH concentrations rise, hepatic IGF-1 production also increases. This endocrine pathway is relevant to ongoing research on anabolic signaling, connective tissue physiology, and metabolic regulation, although compound-specific clinical outcome data for CJC-1295 remain limited.
One finding that distinguishes CJC-1295 from exogenous recombinant GH is that it appears to preserve pulsatile GH secretion patterns rather than flattening them. Research published by Ionescu and Frohman in the Journal of Clinical Endocrinology & Metabolism (2006) showed that GH pulse architecture remained intact during continuous CJC-1295 stimulation, which is not typically the case with direct GH administration.
Pairing CJC-1295 with Ipamorelin adds another layer to this picture. The two compounds act on separate receptor pathways:
- CJC-1295: GHRH receptor stimulation
- Ipamorelin: Growth hormone secretagogue receptor (GHS-R) activation
Because they work through different mechanisms, the combination is sometimes described as complementary in investigational use; however, this should not be presented as an established clinical outcome without stronger controlled evidence.
CJC-1295 Benefits
All applications below should be interpreted within the limitations of the available evidence. Large-scale, long-term randomized controlled trials for CJC-1295 are still limited, and findings from early-phase and preclinical studies should be interpreted accordingly.
Lean Muscle Growth and IGF-1 Elevation
Early human data from Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism (2006), showed dose-dependent increases in both GH and IGF-1 following CJC-1295 administration in healthy adults. Given IGF-1’s role in protein synthesis and anabolic signaling, CJC-1295 for muscle growth has become a frequent topic in practitioner literature, where it is often framed as a research-grade muscle-growth peptide in body-composition protocols.
However, robust hypertrophy-focused randomized controlled trials have not yet been completed.
Body Composition and Weight Loss
Growth hormone plays a well-established role in fat breakdown (lipolysis) and energy metabolism, particularly in visceral fat. Practitioner-reported research on CJC-1295 peptide therapy frequently focuses on body composition and weight-loss support via GH-mediated fat oxidation and lean mass preservation.
Recovery and Connective Tissue Support
Preclinical data and practitioner-reported observations suggest that elevated GH and IGF-1 may support connective tissue repair, collagen turnover, and shorter recovery windows between training sessions. In recovery-oriented research, CJC-1295 is sometimes discussed alongside other compounds as a performance peptide, though direct evidence specific to CJC-1295 in this context remains extrapolated.
Sleep Quality
Since the body releases most of its endogenous GH during sleep, some researchers and practitioners have explored whether pre-sleep administration of CJC-1295 could amplify the body’s natural nocturnal GH pulses. Direct human evidence for sleep-specific outcomes remains limited.
CJC-1295 Dosage and Administration
All dosing information below comes from published research protocols, early-phase studies, and practitioner-reported practices. No FDA-approved dosing standard exists for CJC-1295.
For the DAC formulation:
- Once-weekly dosing is commonly discussed in investigational and practitioner-reported contexts because of the compound’s prolonged half-life
Early pharmacokinetic data suggest that steady-state IGF-1 elevation tends to become more apparent after approximately 2 to 4 weeks of repeated administration.
Lyophilized CJC-1295 is typically reconstituted with bacteriostatic water and stored refrigerated at 2 to 8°C, away from direct light. Researchers and practitioners buying online or ooking to buy CJC-1295 online should look for suppliers that provide third-party purity verification, documented storage handling procedures, and batch consistency records.
When Ipamorelin is included in investigational protocols, it is typically discussed separately because of its shorter duration of action. Any formulation-specific dosing references for Ipamorelin should be presented as practitioner-reported or research-derived rather than standardized clinical guidance.
Ipamorelin’s dosing schedule is independent of the weekly CJC-1295 injection, and the two are not typically administered at the same time.
Researchers and practitioners should verify the exact formulation under evaluation, as dosing frequency differs significantly between DAC and non-DAC variants. Those looking to buy CJC-1295 wholesale for institutional or multi-practitioner research settings can contact Medica Depot’s support representatives for guidance and directions on documentation, supplier review, and purchase pathways.
Legal and Regulatory Status
Regulatory classifications can shift, so practitioners should confirm current local requirements before evaluating or sourcing any peptide compound. Research institutions reviewing their procurement options may also find it useful to compare wholesale pricing structures across suppliers for laboratory or multi-practitioner environments.
They may also compare online purchase terms, minimum order requirements, and documentation standards before selecting a supplier.
- United States: CJC-1295 is not approved by the U.S. Food and Drug Administration for therapeutic use. FDA materials on bulk substances used in compounding indicate that certain peptide substances, including CJC-1295, have been associated with safety risks in the compounding context, so practitioners should verify current FDA guidance before evaluating procurement or use pathways.
- Australia: CJC-1295 is not approved by the TGA for therapeutic use and is classified as a research compound. Practitioners should verify current TGA scheduling and compounding requirements before evaluation or procurement.
- WADA Classification: Growth hormone secretagogues, including CJC-1295, are prohibited at all times — both in competition and out of competition — under the WADA S2 category covering peptide hormones, growth factors, related substances, and mimetics. Practitioners working with competitive athletes should communicate this prohibition clearly and advise athletes to verify the current WADA Prohibited List independently.
CJC-1295 Side Effects & Safety Profile
No large-scale, long-term human safety trials have been completed for CJC-1295. The current safety picture is drawn from early human studies, broader GHRH analogue class data, and practitioner-reported observations — a gap that should be communicated clearly when presenting this compound in any research context.
- Water Retention and Mild Edema: Biologically plausible considerations with GH/IGF-1 elevation, but long-term safety characterization for CJC-1295 remains limited because the human evidence base is still small.
- Injection Site Reactions: Subcutaneous administration may cause mild redness, swelling, or irritation at the injection site. These reactions are generally short-lived.
- IGF-1-Related Considerations: Early human studies show sustained IGF-1 elevation after CJC-1295 administration, but the interpretation of broader long-term risks should not be overstated beyond the available evidence.
CJC-1295 vs Sermorelin vs Tesamorelin vs Ipamorelin
| Compound | Drug Class | Primary Focus | Approximate Half-Life | Regulatory Status |
| CJC-1295 with DAC | GHRH analogue | Sustained GH and IGF-1 elevation | 5.8–8.1 days | Not FDA-approved; often marketed for research use |
| Sermorelin | GHRH analogue | Pulsatile GH stimulation | 10–20 minutes | Previously used clinically in limited contexts; current regulatory and market status should be verified |
| Tesamorelin | GHRH analogue | Visceral fat reduction in HIV lipodystrophy | Approximately 30 minutes | FDA-approved for HIV-associated lipodystrophy |
| Ipamorelin | GHS-R agonist | Selective GH pulse initiation | Approximately 2 hours | Not FDA-approved; regulatory status varies by jurisdiction |
A key pharmacokinetic distinction of CJC-1295 with DAC is its longer reported half-life in early human studies. Sermorelin and Tesamorelin both produce shorter windows of GH stimulation and require more frequent dosing to maintain effect.
Ipamorelin is mechanistically distinct, acting through the ghrelin receptor rather than the GHRH receptor. That distinction is why Ipamorelin is most often evaluated as a complement to CJC-1295 rather than an alternative.
Where Can Practitioners Buy CJC-1295 Online?
CJC-1295 is available for procurement exclusively by qualified professionals who need this GHRH analogue for laboratory or investigational use. Sourcing should be limited to suppliers that provide verifiable purity documentation, certificate of analysis, LOT number traceability, formulation-specific identity testing confirming DAC vs non-DAC variant, and cold-chain compliance records. Medica Depot provides documentation guidance and procurement directions for qualified professionals evaluating research-grade GH-axis peptides online, including wholesale, purchase, and order-related documentation review.
Contact Medica Depot’s support representatives for guidance and directions on sourcing documentation, order-related references, and available product information.
FAQs
1. What is CJC-1295 used for in research?
CJC-1295 is a long-acting GHRH analogue that stimulates pulsatile growth hormone release from the pituitary gland. Its DAC modification extends its half-life to approximately 8 days, which supports once-weekly dosing. In research settings, it is primarily evaluated for its effects on GH and IGF-1 modulation, body composition, and recovery. It is a research compound and has not been approved for therapeutic use.
2. What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC binds to albumin in the bloodstream, extending its half-life to approximately 5.8 to 8.1 days and supporting once-weekly dosing. The version without DAC, commonly known as Modified GRF 1-29, has a half-life of roughly 30 minutes and needs to be administered multiple times daily. Both versions work through the same receptor, but they produce different GH release patterns as a result of that half-life difference.
3. Why is CJC-1295 commonly combined with Ipamorelin?
CJC-1295 and Ipamorelin act through different receptor systems, so they are often discussed together in investigational peptide protocols. However, claims of additive clinical benefit should be interpreted with caution because controlled human evidence on combination outcomes remains limited.
4. Is CJC-1295 FDA-approved?
In the United States, CJC-1295 is not FDA-approved for therapeutic use. It is also prohibited under WADA’s S2 category, which is relevant for tested athletes and sports medicine settings. Regulatory treatment varies by country, so local requirements should be reviewed before any evaluation or procurement decision.
5. How does CJC-1295 compare with Sermorelin?
Both are GHRH analogues, but the similarities largely end there. Sermorelin has a half-life of approximately 10 to 20 minutes and requires more frequent administration, while CJC-1295 with DAC is designed for prolonged exposure on a once-weekly schedule. Sermorelin had historical FDA approval (since withdrawn for commercial reasons, not safety concerns); CJC-1295 is a research compound only.
Citations
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490
For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.
Recommended PRODUCTS
